Cambrian Bio, based in New York, builds a pipeline of therapies for age-related disease and healthy ageing, including the TORnado platform of selective mTORC1 inhibitors. In February 2026 it was awarded up to $30.8 million under ARPA-H's PROSPR programme.
At a glance
| Price from | Custom |
| Best for | Partners interested in next-generation rapamycin drugs |
From Cambrian Bio's own website.
What stands out
- US government backing for trials
- Builds on well-studied rapamycin biology
Worth knowing
- Latest equity funding not disclosed
- Early clinical stage
How it ranks
Cambrian Bio is ranked 9th of 10 in Best Longevity Startups (Lister Score 86.4).
#9 in Best Longevity Startups · Lister Score 86.4
The ARPA-H award supports human trials of a daily oral mTORC1 inhibitor aimed at improving intrinsic capacity in older people..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Cambrian Bio rank on Lister?
Cambrian Bio is ranked 9th of 10 in Best Longevity Startups (Lister Score 86.4).
Appears in
Add this badge to your site
If you work at Cambrian Bio, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.